New hope for early lung cancer: drug combo aims to stop return after surgery

NCT ID NCT06564844

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 28 times

Summary

This study tests whether a new combination of drugs (datopotamab deruxtecan plus rilvegostomig) or rilvegostomig alone can keep early-stage lung cancer from returning after surgery. It includes 24 people with stage I adenocarcinoma non-small cell lung cancer who have signs of cancer DNA in their blood or other high-risk features. The goal is to see if these treatments work better than standard care.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Research Site

Tucson, Arizona, 85724, United States
Research Site

Duarte, California, 91010, United States
Research Site

Glendale, California, 91204, United States
Research Site

Los Angeles, California, 90089, United States
Research Site

Lone Tree, Colorado, 80124, United States
Research Site

Washington D.C., District of Columbia, 20007, United States
Research Site

Jacksonville, Florida, 32224, United States
Research Site

St. Petersburg, Florida, 33709, United States
Research Site

Chicago, Illinois, 60637, United States
Research Site

Evanston, Illinois, 60201, United States
Research Site

Zion, Illinois, 60099, United States
Research Site

Kansas City, Kansas, 66160, United States
Research Site

Lexington, Kentucky, 40503, United States
Research Site

Baltimore, Maryland, 21237, United States
Research Site

Farmington Hills, Michigan, 48334, United States
Research Site

Grand Rapids, Michigan, 49503, United States
Research Site

Minneapolis, Minnesota, 55407, United States
Research Site

Billings, Montana, 59102, United States
Research Site

Omaha, Nebraska, 68130, United States
Research Site

East Syracuse, New York, 13057, United States
Research Site

Mineola, New York, 11501, United States
Research Site

New York, New York, 10016, United States
Research Site

New York, New York, 10065, United States
Research Site

Portland, Oregon, 97239, United States
Research Site

Bethlehem, Pennsylvania, 18015, United States
Research Site

Philadelphia, Pennsylvania, 19107, United States
Research Site

Pittsburgh, Pennsylvania, 15212, United States
Research Site

Knoxville, Tennessee, 37920, United States
Research Site

Memphis, Tennessee, 38120, United States
Research Site

Nashville, Tennessee, 37203, United States
Research Site

Austin, Texas, 78745, United States
Research Site

Dallas, Texas, 75231, United States
Research Site

Houston, Texas, 77030, United States
Research Site

San Antonio, Texas, 78217, United States
Research Site

Fairfax, Virginia, 22031, United States
Research Site

Edmonds, Washington, 98026, United States
Research Site

Seattle, Washington, 98104, United States
Research Site

Madison, Wisconsin, 53792, United States
Research Site

Barretos, 14784-057, Brazil
Research Site

Brasília, 70200-730, Brazil
Research Site

Florianópolis, 88034-000, Brazil
Research Site

São Paulo, 01323-903, Brazil
Research Site

Teresina, 64049-200, Brazil
Research Site

Halifax, Nova Scotia, B3H 2Y9, Canada
Research Site

Oshawa, Ontario, L1G 2B9, Canada
Research Site

Greenfield Park, Quebec, J4V 2H1, Canada
Research Site

Montreal, Quebec, H2X 3J4, Canada
Research Site

Saskatoon, Saskatchewan, S7M 0Z9, Canada
Research Site

Hong Kong, 999077, Hong Kong
Research Site

Bunkyō City, 113-8603, Japan
Research Site

Chiba, 260-0877, Japan
Research Site

Chūōku, 104-0045, Japan
Research Site

Fukuoka, 812-8582, Japan
Research Site

Hidaka-shi, 350-1298, Japan
Research Site

Hiroshima, 730-8518, Japan
Research Site

Hiroshima, 734-8551, Japan
Research Site

Iwakuni-shi, 740-8510, Japan
Research Site

Kashiwa, 277-8577, Japan
Research Site

Kitaadachi-gun, 362-0806, Japan
Research Site

Kobe, 650-0017, Japan
Research Site

Kōtoku, 135-8550, Japan
Research Site

Kumamoto, 860-8556, Japan
Research Site

Nagoya, 464-8681, Japan
Research Site

Niigata, 951-8566, Japan
Research Site

Osakasayama-shi, 589-8511, Japan
Research Site

Sapporo, 003-0804, Japan
Research Site

Sendai, 980-0873, Japan
Research Site

Sendai, 980-8574, Japan
Research Site

Wakayama, 641-8510, Japan
Research Site

Yokohama, 241-8515, Japan
Research Site

Kuala Lumpur, 50586, Malaysia
Research Site

Kuala Lumpur, 59100, Malaysia
Research Site

Kuching, 93586, Malaysia
Research Site

Kaohsiung City, 80756, Taiwan
Research Site

Taipei, 10002, Taiwan
Research Site

Taipei, 112, Taiwan
Research Site

Taipei, 114, Taiwan
Research Site

Taoyuan, 333, Taiwan
Research Site

Bangkok, 10400, Thailand
Research Site

Bangkoknoi, 10700, Thailand
Research Site

Banphaeo, 74120, Thailand
Research Site

Dusit, 10300, Thailand
Research Site

Hat Yai, 90110, Thailand
Research Site

Muang, 40002, Thailand
Research Site

Muang, 50200, Thailand
Research Site

Ratchathewi, 10400, Thailand
Research Site

Ankara, 06010, Turkey (Türkiye)
Research Site

Ankara, 06280, Turkey (Türkiye)
Research Site

Istanbul, 34214, Turkey (Türkiye)
Research Site

Mersin, 33240, Turkey (Türkiye)
Research Site

Leeds, LS9 7TF, United Kingdom
Research Site

London, SE1 9RT, United Kingdom
Research Site

Nottingham, NG5 1PB, United Kingdom
Research Site

Da Nang, 550000, Vietnam
Research Site

Hanoi, 100000, Vietnam
Research Site

Hà Nội, 100000, Vietnam
Research Site

Ho Chi Minh City, 700000, Vietnam
Research Site

Ho Chi Minh City, 70000, Vietnam
Research Site

Vinh, 460000, Vietnam

Conditions

Explore the condition pages connected to this study.

NON-SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CANCER